Neurology

Eli Lilly and Co. is seeking U.S. Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after the recently approved Leqembi from Japanese drugmaker Eisai.

The research, published in the medical journal Pediatrics on Monday, is drawn from emergency room visits to U.S. and Canadian children’s hospitals.

Tests measure the concentration of three characteristic biomarkers of Alzheimer's disease in the cerebrospinal fluid.

Study reveals a new possible target for drug development.

In this ongoing series, we look at the common signs and symptoms of Multiple Sclerosis—and what to do about them. this time—What is MS gait?

Beyond providing a harmonized definition of death, guidelines present updated criteria for determining death in the event of devastating brain injury or circulatory arrest.

Recent research found the changes become more pronounced as time goes on.

What better way to start the summer than with a resolution to eat better! Test your knowledge of processed foods, and more specifically their impact on the brain.